JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com -- Shares of Fresenius Medical Care (ETR:FMEG) rose more than 3% on Tuesday after the company reported first-quarter results that beat expectations, despite flat treatment growth in its key U.S. market.
Sales for the quarter were 1% above consensus, while adjusted EBIT and adjusted earnings per share exceeded forecasts by 2% and 11%, respectively, according to Deutsche Bank (ETR:DBKGn) Research.
Organic sales grew 5%, with contributions from both dialysis services and dialysis products.
Adjusted EBIT rose 11% at constant currency, lifting the margin to 9.4%. While U.S. same-market treatment growth was flat, Deutsche Bank analysts said this was expected due to a severe flu season.
The Care Delivery segment saw 4% organic growth, with U.S. sales rising 3%. Adjusted EBIT for the unit improved modestly, supported by price effects and cost savings.
The Care Enablement segment posted 5% sales growth and a 50% jump in adjusted EBIT, driven by pricing, volume, and ongoing efficiency gains.
Fresenius confirmed its 2025 outlook, projecting low-single-digit sales growth in constant currency and an adjusted EBIT margin of 11% to 12%, helped by continued cost-cutting efforts. U.S. treatment growth is expected to exceed 0.5% next year.
However, Deutsche Bank noted that foreign exchange trends, particularly a weaker U.S. dollar, could weigh on earnings.